Tuesday, May 30, 2023

Sun Pharma, Philogen join hands to commercialise skin cancer drug in Europe, Australia, New Zealand

Sun Pharma, Philogen join hands to commercialise skin cancer drug in Europe, Australia, New Zealand The companies have come together to commercialise Philogen#39;s speciality product Nidlegy, an anti-cancer biopharmaceutical currently in Phase III clinical trials, Sun Pharma said in a statement.

from Moneycontrol Business News https://ift.tt/NmKcOvj
at
Labels: , , ,

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)

LTIMindtree Q4 Preview: Lower pass-through revenue seen impacting growth marginally

A compilation of estimates suggests the company#39;s Q4 FY24 net profit is projected to decline by 2.2 percent quarter on quarter to Rs 1,1...